Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Combination effect of orthokeratology and low dose atropine on axial elongation in orthokeratology poor response myopic children
Author Affiliations & Notes
  • Jiwen Yang
    Aier School of Ophthalmology, Liaoning Aier Eye Hospital, Central South University, Shenyang, China, China
  • Bo Wu
    Dongguan Aier Eye Hospital Affiliated to Jinan University, China
  • Danyu Sun
    Shenzhen Aier Hospital, Aier Eye Hospital, Jinan University, Shenzhen, China, China
  • Jin Xu
    Shenzhen Aier Hospital, Aier Eye Hospital, Jinan University, Shenzhen, China, China
  • Zhengfei Yang
    Shenzhen Aier Hospital, Aier Eye Hospital, Jinan University, Shenzhen, China, China
  • Footnotes
    Commercial Relationships   Jiwen Yang None; Bo Wu None; Danyu Sun None; Jin Xu None; Zhengfei Yang None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2703. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jiwen Yang, Bo Wu, Danyu Sun, Jin Xu, Zhengfei Yang; Combination effect of orthokeratology and low dose atropine on axial elongation in orthokeratology poor response myopic children. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2703.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : It is imperative to mitigate the onset of high myopia by minimizing the progression of myopia during early childhood. Orthokeratology (OK) is a clinical technique that uses specially designed rigid contact lenses to reshape the cornea to temporarily reduce or eliminate refractive error. However, it has been observed that young children may exhibit poor response to OK, as they continue to experience rapid progression of myopia despite its use. We performed a retrospective study to compare the effectiveness of the combined treatment of low-dose atropine and OK in controlling myopia in children with a poor response to OK.

Methods : 91 children who experienced two years of OK treatment were analyzed in this retrospective study. They were aged between 6-12 years old. when they started OK treatment. All children showed an annual increase of 0.3mm or greater in the first year of treatment of OK. The children with combination treatment with 0.01% atropine in the second year were defined as the OKA 0.01% group, and combination treatment with 0.05% atropine was defined as the OKA 0.05% group. The monotherapy of the OK (monoOK) group included children without any combined atropine therapy in the second year. This study analyzed the change in AL in the second years. The difference in the AL of the second year among the three groups was also analyzed.

Results : Results: There was no significant difference between the OKA 0.01% group and the monoOK group in the second year (P=0.735) in AL. However, OKA 0.05% showed shorter AL than the OKA 0.01% group (P=0.035) and the monoOK group (P=0.001) in the second year. The AL change of the second year in the OKA 0.05% group was smaller than the OKA 0.01% group (P=0.031) and monoOK group (P<0.001), and there was no significant difference between OKA 0.01 and the monoOK group (P=0.755). The AL change of the second year in the OKA 0.05% group was correlated with baseline AL (R=0.84, P<0.001), and was not correlated with age (P=0.243), gender (P=0.184) and the change of pupil diameter after atropine usage (P=0.948).

Conclusions : For the OK poor response in young children, additive use of 0.05% atropine can control the fast progress of axial elongation elongation compared to combining 0.01% atropine.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×